254 related articles for article (PubMed ID: 34431253)
1.
Kaneko E; Sato N; Sugawara T; Noto A; Takahashi K; Makino K; Terada Y
J Gynecol Oncol; 2021 Nov; 32(6):e79. PubMed ID: 34431253
[TBL] [Abstract][Full Text] [Related]
2. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
3. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
4. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
[TBL] [Abstract][Full Text] [Related]
5. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
Pasanen A; Loukovaara M; Bützow R
Mod Pathol; 2020 Jul; 33(7):1443-1452. PubMed ID: 32060377
[TBL] [Abstract][Full Text] [Related]
8. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
[No Abstract] [Full Text] [Related]
9. Mismatch Repair Protein Expression in Endometrioid Intraepithelial Neoplasia/Atypical Hyperplasia: Should We Screen for Lynch Syndrome in Precancerous Lesions?
Lucas E; Chen H; Molberg K; Castrillon DH; Rivera Colon G; Li L; Hinson S; Thibodeaux J; Lea J; Miller DS; Zheng W
Int J Gynecol Pathol; 2019 Nov; 38(6):533-542. PubMed ID: 30383610
[TBL] [Abstract][Full Text] [Related]
10. Endometrial Carcinomas With Subclonal Loss of Mismatch Repair Proteins: A Clinicopathologic and Genomic Study.
Mendoza RP; Wang P; Schulte JJ; Tjota MY; Jani I; Martinez AC; Haridas R; Wanjari P; Steinhardt G; Brown N; Betz BL; Chapel DB; Kertowidjojo E; Yamada SD; Bennett JA
Am J Surg Pathol; 2023 May; 47(5):589-598. PubMed ID: 36866757
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG
Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859
[TBL] [Abstract][Full Text] [Related]
12. MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation Status.
Kurpiel B; Thomas MS; Mubeen M; Ring KL; Modesitt SC; Moskaluk CA; Mills AM
Int J Gynecol Pathol; 2022 Jan; 41(1):1-11. PubMed ID: 33577226
[TBL] [Abstract][Full Text] [Related]
13. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
[TBL] [Abstract][Full Text] [Related]
14. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.
Buchanan DD; Tan YY; Walsh MD; Clendenning M; Metcalf AM; Ferguson K; Arnold ST; Thompson BA; Lose FA; Parsons MT; Walters RJ; Pearson SA; Cummings M; Oehler MK; Blomfield PB; Quinn MA; Kirk JA; Stewart CJ; Obermair A; Young JP; Webb PM; Spurdle AB
J Clin Oncol; 2014 Jan; 32(2):90-100. PubMed ID: 24323032
[TBL] [Abstract][Full Text] [Related]
15. Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers.
Evans DG; Lalloo F; Ryan NA; Bowers N; Green K; Woodward ER; Clancy T; Bolton J; McVey RJ; Wallace AJ; Newton K; Hill J; McMahon R; Crosbie EJ
J Med Genet; 2022 Apr; 59(4):328-334. PubMed ID: 33452216
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Clinicopathologic Analysis for Mismatch Repair Protein Expression in Unselected Endometrial Carcinoma Patients With an Emphasis on the Role of MLH1 Deficiency.
Huang SW; Lin H; Huang CC; Ou YC; Fu HC; Tsai CC; Changchien CC; Wu CH
Int J Gynecol Pathol; 2022 Jul; 41(4):407-416. PubMed ID: 34347667
[TBL] [Abstract][Full Text] [Related]
17. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
18. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
[TBL] [Abstract][Full Text] [Related]
19. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
